David S. Barlow
Chair & CEO
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Dr. William (Bill) Carlezon helps guide Psy’s Major Depressive Disorder (MDD) program and is an active member of the Scientific Advisory Board. Dr. Carlezon is well-known for his work on the neurobiology of depression and addiction, and brings unparalleled expertise in MDD as well as a dedication to treating psychiatric illness.
Dr. Carlezon is a Professor of Psychiatry and Neuroscience at Harvard Medical School. His laboratory is based at McLean Hospital, where he serves as Chief of the Basic Neuroscience Division and Principal Investigator on an NIMH Silvio O. Conte Center. Dr. Carlezon’s orientation to drug development draws on experience gained when he worked in the research laboratories of Hoechst-Roussel Pharmaceuticals.
Dr. Carlezon’s primary interest is the biological basis and treatment of neuropsychiatric illness, specifically nature/nurture issues as they relate to the brain and the underlying processes by which the brain develops and is modified in response to experience. His laboratory is currently focused on understanding how the environment – including exposure to stress, trauma, drug abuse, toxins and illness – affects behavior and the biology of the brain, and developing and implementing more objective endpoints for analysis. This work is relevant to many types of neuropsychiatric disorders, including depression, anxiety, PTSD, addiction and autism.
Dr. Carlezon has received numerous awards for his research, including:
Dr. Carlezon received a BSc from Bates College and a PhD from Concordia University (Montreal). He completed a postdoctoral fellowship focused on molecular psychiatry at Yale University School of Medicine.